BACKGROUND AND
OBJECTIVE: Morphine withdrawal increases the neuronal
activity in the brain associated with the changes in the level of
neurotransmitters and second messenger system. The aim of this study was to
evaluate the effect of felodipine (calcium channel blocker) alone and in
combination with CCPA (A1 receptor agonist) or SCH58261 (A2A receptor
antagonist) on the morphine withdrawal syndrome.
METHODS: This
experimental study was conducted on 80 NMRI male mice divided into 8 groups
(n=10) including Saline, Felodipine (2.5, 5, 10 mg/kg), CCPA, SCH58261,
Felodipine+CCPA, and Felodipine+SCH groups. Animals received increasing doses
of morphine sulphate subcutaneously (S.C). Animals were
examined in terms of jumping behavior and diarrhea for 30 minutes after intraperitoneal (i.p.) injection of naloxone (4 mg/kg i.p.).
FINDINGS: In comparison with the saline group, 5
mg/kg of Felodipine (88.1±7.199 & 44.8± 8.421, p<0.05), CCPA (88.1±7.199
& 20.4± 5.02, p<0.001) and SCH (88.1±7.199 & 37.2± 3.623,
p<0.001) significantly reduced the number of jumps. Three doses (2.5, 5 and
10 mg/kg) of felodipine decreased the amount of diarrhea (0.478±0.059,
0.109±0.035, p<0.001), (0.478±0.059, 0.112±0.054, p<0.001), (0.478±0.059,
0.067±0.026, p<0.001), respectively and the CCPA significantly reduced diarrhea
(0.478±0.059, 0.057±0.010, p<0.001), too. In the combination therapy, Felodipine
(5mg/kg) +CCPA significantly decreased jumping (88.1±7.199 & 28.3±4.758,
p<0.001) and diarrhea (0.478±0.59 & 0.011±0.007, p<0.001). Felodipine
(5mg/kg) +SCH 58261 significantly reduced jumping (88.1±7.199 & 41.7±5.226,
p<0.001) and diarrhea (0.478±0.59 & 0.027±0.023, p<0.001).
CONCLUSION: The
results showed that using the felodipine in combination with SCH58261 and CCPA
decreased morphine withdrawal symptoms, but synergistic effect was not observed
in combination therapy.